Quantcast
Channel: Endpoints News
Viewing all articles
Browse latest Browse all 2200

FDA denies Ocaliva full approval, but Intercept hopes to keep drug on market

$
0
0
The FDA rejected the full approval submission for Intercept Pharmaceuticals and Alfasigma’s primary biliary cholangitis treatment Ocaliva after safety concerns dogged the product, casting its future into doubt. While Intercept

Viewing all articles
Browse latest Browse all 2200

Trending Articles